An Observational Chart Review on the Efficacy of Subcutaneous Methotrexate in Mild to Moderate Ulcerative Colitis and the Description of Occurrence of Adenomatous Polyps in Afflicted Patients
DOI:
https://doi.org/10.17140/GOJ-1-106Keywords:
Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD); Methotrexate (MTX), Subcutaneous (SC), Mayo Disease Activity Index (Mayo DAI), Inflammatory Bowel Disease Questionnaire (IBDQ)Abstract
Ulcerative Colitis (UC) is a type of Inflammatory Bowel Disease (IBD) that affects the large intestine and produces mainly symptoms of abdominal pain and bloody stools. Chart reviews of patients from July 2011 to July 2012 with mild to moderate UC enrolled in a com munity-based NIH trial on the efficacy of 8 weeks of 12.5 mg once daily subcutaneous methotrexate demonstrated no significant improvement of abdominal pain and bloody stools. In their patient diaries and IBD Questionnaire, all 9 patients reported a sense of heaviness or abdominal fullness, bloating or cramps. The patients experienced decreased energy levels and depressed feelings with anxiety and decreased sleep at night. Overall, the majority of them reported a decreased quality of life despite the 8 week trial of MTX. We also noted in the chart review the incidental finding of histopathologically-confirmed distal adenomatous polyps in all 9 patients for which we postulate the following: 1) that distal adenomatous polyps may be a risk factor in UC, 2) that surgical removal or polypectomy for these polyps, if diagnosed earlier especially in those younger than 40 years of age, may delay progression or prevent development of UC, 3) the presence of polyps in all 9 patients could have prevented the desired therapeutic response from methotrexate, and 4) that the presence of the polyps may indicate that low dose methotrexate is not an effective treatment for UC. The presence of intestinal polyps realigns the structural integrity and dynamics of the movement of the intestinal walls and valves, causing affected patients to frequently report feelings of discomfort and lethargy. It is important to understand that further diagnosis and therapies for UC and IBD are accompanied with ethical questions, such as treating affected patients with cytotoxic medications and performing colonoscopies under the standard age care of 50 years. Further research needs to address combination therapies and other risk factors such diets and preservatives to determine the full extent of this potential ground-breaking science.
References
Mahadevan U. Medical Treatment of Ulcerative Colitis. Clin Colon Rectal Surg. 2004; 17(1): 7-19. doi: 10.1055/s-2004- 823066
Searles G, McKendry RJ. Methotrexate pneumonitis in rheu-matoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987; 14: 1164-1171.
Loftus EV Jr. Clinical epidemiology of IBD: incidence, prev-alence, and environmental influences. Gastroenterology. 2004; 126: 1502-1517. doi: 10.1053/j.gastro.2004.01.063
Moum B, Vatn MH, Ekbom A, et al. Incidence of inflamma-tory bowel disease in southeastern Norway: evaluation of meth-ods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroentrologists. Digestion. 1995; 56: 377-381.
Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11.
Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996; 31: 260- 266.
Tuckson WB. Ulcerative Colitis. American Soc of Colon and Rectal Surgeons. 2012.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately ac-tive UC. N Engl J Med. 1987; 317: 1625-1629 doi: 10.1056/ NEJM198712243172603
Williams CN. Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of UP: a review of 2 double-blind, placebo-controlled trials. Can J Gastroenterol. 1990; 4: 472- 475.
Hamilton Ra, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheu-matoid arthritis. Br J Rheumatol. 1997; 36: 86-90. doi: 10.1093/ rheumatology/36.1.86
Kornbluth A, Sachar DB. UC practice guidelines in adults (update): American College of Gastroenterology, practice pa-rameters committee. Am J Gastroenterol. 2004; 99(7): 1371- 1385. doi: 10.1111/j.1572-0241.2004.40036.x
Nielsen OH, Munck LK. Drug insight: Aminosalicylates for the treatment of IBD. Nature Clinical Practice, Gastroenterol-ogy and Hepatology. 2007; 4(3): 1060-1070. doi: 10.1038/ncp-gasthep0696
Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. IBD. 2004; 10(6): 731-736. doi: 10.1097/00054725-200411000-00006
Stein RB, Hanauer SB. Comparative tolerability of treat-ments for inflammatory bowel disease. Drug Saf. 2000; 23: 429- 448. doi: 10.2165/00002018-200023050-00006
Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal UC, proctosigmoiditis, and proctitis. Gastroeneterology. 1987; 92(7): 1894-1898. doi: 10.1007/BF01312466
US Preventive Serv Task force. Recommendation Summary Colorectal Cancer Screening. Website: http://www.uspreven-tiveservicestaskforce.org/Page/Document/Recommendation-StatementFinal/colorectal-cancer-screening. Accessed 2014; 2014.
Moss MC, Peppercorn MA. The risks and benefits of me-salazine as a treatment for UC. Expert Opin. Drug Saf. 2007; 6(2): 99-107. doi: 10.1517/14740338.6.2.99
Oren R, Arben N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996; 110: 1416-1421. doi: 10.1053/gast.1996.v110.pm8613046
Reinisch W, Sandborn WJ, Bala M, et al. Response and re-mission are associated with improved quality of life, employ-ment and disability status, hrs. worked, and productivity of patients with UC. IBD. 2007; 13(0): 1135-1140. doi: 10.1002/ ibd.20165
Clinical Trials of the US NIH. Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis (Mer-it-UC). NCT01393405; 2014 to present. Website: https://clini-caltrials.gov/ct2/show/NCT01393405. 2011; Accessed 2015.
Methotrexate. Anticancer drugs. Website: http://medical-textbooksrevealed.s3.amazonaws.com/files/16681-53.pdf. 2014; Accessed 2015.
Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study in efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacy Ther. 2002; 16: 1751-1759. doi: 10.1046/j.1365-2036.2002.01340.x
Payne S and Miles D. Mechanisms of anticancer drugs. Edited by Michael Gleeson. CRC press. 2008. doi: 10.1201/ b15118-6
Swierkot J, Szechinski J. Methotrexate in rheumatoid arthri-tis. Pharmacol Rep. 2006; 58: 473-492.
Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008; 47: 249- 255. doi: 10.1093/rheumatology/kem279
Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Inves-tigators. N Engl J Med. 2000; 342: 1627-1632. doi: 10.1056/ NEJM200006013422202
Herfarth HH, Osterman MT, Isaacs KL, Lewis JD, Sands BE. Efficacy of Methotrexate in ulcerative colitis: failure or prom-ise. Inflamm Bowel Dis. 2010; 16(8): 1421-1430. doi: 10.1002/ ibc.21246
Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-con-trolled trial. Hepatogastroenterology. 1999; 46: 1724-1729
Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003; 18: 57-63. doi: 10.1046/j.1365-2036.2003.01614.x
Cummings JR, Herrlinger KR, Travis SP, et al. Oral metho-trexate in ulcerative colitis. Aliment Pharmacol Ther. 2005; 21: 385-389. doi: 10.1111/j.1365-2036.2005.02331.x
D’Haens G, Sandborn WJ, Feagan BG, et al. A review of ac-tivity indices and efficacy end points for clinical trials of medical therapy in adults with UC. Gastroenterology. 2007; 132: 763- 786. doi: 10.1053/j.gastro.2006.12.038
Alsufyam K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 31: 179-182.
Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990; 33: 91-94. doi: 10.1002/art.1780330112
Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993; 20: 1845-1849.
Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral admin-istration of methotrexate in patients with active rheumatoid ar-thritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81. doi: 10.1002/art.23144
Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 1999; 13: 1597-1604. doi: 10.1046/ j.1365-2036.1999.00667.x
Egan LJ, Sandborn WJ, Tremaine JA, et al. A randomized, single – blind, pharmacokinetic and dose response study of sub-cutaneous methotrexate, 15 and 25 mg/week for refractory ul-cerative colitis. Gastrojournal.org. 1998.
Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of Correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995; 22: 844-849.
Teresi ME, Crom WR, Choi KE, et al. Methotrexate bio-availability after oral and intramuscular administration in chil-dren. J Pediatr. 1987; 110: 788-792.
Axcan Pharma. A multicenter, double-blind, controlled, randomized, parallel group comparison phase IIIa treatment investigation on the efficacy and safety of MAX-002 supposi-tory versus placebo and active medicine in mild to moderate ulcerative proctitis. Website: http://adisinsight.springer.com/ trials/700051376. 2010; Accessed 2011.
Kitiyakara T, Bailey DM, McIntyre AS, Gorard DA. Ad-enomatous colonic polyps are rare in ulcerative colitis. Ali-ment Pharmacol Ther. 2004; 19(8). doi: 10.1111/j.1365-2036- .2004.01914.x
Dixon A, Wurm P, Hart A, Robinson R. Distal adenoma-tous polyps are rare in patients with inflammatory bowel dis-ease. Postgrad Med Journ. 2006; 82: 76-78. doi: 10.1136/ pgmj.2005.033779
Mayo Clinic. Colon polyps. Mayo Foundation for Medical education and research. Website: http://www.mayoclinic.org/dis-eases-conditions/colon-polyps/basics/definition/con-20031957. 2015; Accessed 2015.
Hanauer SB, Present DH. The state of the art in the manage-ment of IBD. Rev Gastroenterol Disord. 2003; 3(2): 81-92.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.